Karyopharm Therapeutics Inc., a Natick, Massachusetts-based biopharmaceutical company developing small molecule modulators of nuclear transport for the treatment of cancer, autoimmune, dermatologic, and viral diseases, has completed a $10m Series A2 financing.
This latest funding complements the $20m Series A financing announced one year ago (read here).
The round was led by Chione Ltd.
The company intends to use the funds to expand the planned Phase I program, targeted to begin in mid 2012 with its oral selective inhibitors of nuclear export (SINE) for various cancers. Founded in 2008 by Drs. Michael Kauffman, MD, PhD, (CEO), Sharon Shacham, Giulio Draetta and Ronald DePinho, Karyopharm is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.